title: Dual detection of cancer biomarker CA125 using absorbance and electrochemical methods.
abstract: An enzyme-linked immunoassay based on dual signal transduction mechanisms has been developed for detection of ovarian cancer biomarker CA125. The immunoassay uses a nanoelectrode array (NEA) chip and absorbance methods for the dual detection. The NEA is used to confirm the optical detection of CA125 that is carried out in a high-binding 96-well plate. An alkaline phosphatase (AP) enzyme was used to label the detection antibody to allow for both the optical and electrochemical detection of CA125. Two kinds of substrates were catalyzed by the AP enzyme. para-Nitrophenylphosphate (PNPP) produces chromogenic para-nitrophenol (PNP), which can be optically detected at 405 nm. para-Aminophenylphosphate (PAPP) produces electroactive para-aminophenol (PAP), which can be detected amperometrically between -0.1 and 0.3 V. The linear ranges have been determined to be 5-1000 U mL(-1) and 5-1000 U mL(-1) for the optical and electrochemical immunoassays, respectively. The limit of detection of the optical immunoassay is 1.3 U mL(-1) and 40 U mL(-1) for the optical and electrochemical methods, respectively.
authors.affiliation: Department of Biotechnology, College of Science, Baghdad University, Baghdad, Iraq.
authors.forename: Israa
authors.initials: I
authors.lastname: Al-Ogaidi
authors.forename: Zoraida P
authors.initials: ZP
authors.lastname: Aguilar
authors.forename: Savan
authors.initials: S
authors.lastname: Suri
authors.forename: Honglei
authors.initials: H
authors.lastname: Gou
authors.forename: Nianqiang
authors.initials: N
authors.lastname: Wu
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis / Q000737:chemistry*; D018394:CA-125 Antigen / Q000032:analysis / Q000737:chemistry*; D055664:Electrochemical Techniques / Q000379:methods*; D006801:Humans
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen
references.citation: J Ovarian Res. 2009 Oct 09;2:13
references.pmid: 19818123
references.citation: PLoS One. 2011 Mar 15;6(3):e17617
references.pmid: 21423607
references.citation: Anal Chem. 2011 Feb 15;83(4):1167-72
references.pmid: 21244005
references.citation: Eur J Obstet Gynecol Reprod Biol. 2011 Oct;158(2):119-23
references.pmid: 21632171
references.citation: AJR Am J Roentgenol. 2010 Feb;194(2):322-9
references.pmid: 20093591
references.citation: Ann Oncol. 2010 May;21 Suppl 5:v23-30
references.pmid: 20555088
references.citation: Indian J Clin Biochem. 2007 Sep;22(2):17-31
references.pmid: 23105677
references.citation: Clin Chem. 2008 Nov;54(11):1935-9
references.pmid: 18801938
references.citation: Clin Chem. 1991 Sep;37(9):1502-5
references.pmid: 1893575
references.citation: Nanotechnology. 2008 Jul 9;19(27):275301
references.pmid: 21828697
references.citation: Reprod Biol Endocrinol. 2003 Oct 07;1:68
references.pmid: 14577833
references.citation: Am J Clin Pathol. 2006 Jun;125(6):921-7
references.pmid: 16690492
references.citation: Anal Biochem. 2002 Aug 15;307(2):226-34
references.pmid: 12202238
references.citation: J Clin Invest. 1981 Nov;68(5):1331-7
references.pmid: 7028788
references.citation: Anal Chem. 2012 Jan 17;84(2):487-515
references.pmid: 22221172
references.citation: Nat Rev Cancer. 2003 Apr;3(4):267-75
references.pmid: 12671665
references.citation: Anticancer Res. 2005 May-Jun;25(3A):1551-4
references.pmid: 16033059
references.citation: Biomicrofluidics. 2012 Jun;6(2):24104-2410413
references.pmid: 22536308
references.citation: Radiographics. 2003 May-Jun;23(3):687-701
references.pmid: 12740470